SCHEMBL732378

SCHEMBL732378

NS(=O)(=O)c1cncc(Br)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 1/20 0.59
CA2 P00918 8/20 0.46
S100A9 P06702 1/20 0.45
CA9 Q16790 6/20 0.45
CA1 P00915 6/20 0.45
CA3 P07451 1/20 0.45
CA12 O43570 2/20 0.42
PTGS2 P35354 1/20 0.42
POLB P06746 1/20 0.41
HCAR2 Q8TDS4 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
KDM4E B2RXH2 1/20 0.40
EGFR P00533 4/20 0.39
PIK3CD O00329 1/20 0.38
PIK3CG P48736 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11690551 0.84 APLNR (0.71) APLNRCA2CA9CA1CA3
SCHEMBL31375066 0.82 S100A9 (0.44) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL1347132 0.78 S100A9 (0.45) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL30278476 0.78 S100A9 (0.45) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL853773 0.78 PTGS2 (0.48) S100A9PTGS2POLBHCAR2KDM4E
SCHEMBL352138 0.78 S100A9 (0.45) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL26185892 0.78 S100A9 (0.42) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL19820791 0.78 S100A9 (0.39) APLNRS100A9PTGS2POLBHCAR2
SCHEMBL17686065 0.77 CA2 (0.61) CA2CA9CA1CA12PTGS2
Hydrochloric Acid SCHEMBL1368736 0.77 S100A9 (0.44) APLNRS100A9PTGS2POLBHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250230144-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2025-07-17 US disclosed
WO-2025128616-A1 COMPOUNDS FOR TREATING CANCER GENESIS THERAPEUTICS, INC. (US) 2025-06-19 WO disclosed
EP-3841086-B1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2025-04-23 EP disclosed
EP-3541804-B1 CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-22 EP disclosed
EP-3541802-B1 ALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2025-01-01 EP disclosed
US-20240368147-A1 CYCLIN K DEGRADER ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2024-11-07 US disclosed
CN-118852135-A N-acyl sulfonamide compound, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 CN disclosed
EP-4382519-A1 CYCLIN K DEGRADATION AGENT Adlai Nortye Biopharma Co., Ltd. (CN) 2024-06-12 EP disclosed
US-20230322726-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
US-20230322726-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
US-7238808-B2 Acetylenyl-pyrazolo-pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2007-07-03 US disclosed
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME CORP. 2007-02-01 US disclosed
CN-1845915-A Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 MERCK & CO INC (US) 2006-10-11 CN disclosed
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-09-28 US disclosed
WO-2006099972-A1 ACETYLENYL-PYRAZOLO-PVRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2006-09-28 WO disclosed
US-20060160857-A1 Thiazole-4-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2006-07-20 US disclosed
WO-2006074884-A1 THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2006-07-20 WO disclosed
EP-1664018-A1 BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2006-06-07 EP disclosed
WO-2005021529-A1 BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2005-03-10 WO disclosed
US-4094982-A PYRIDINE SULFONAMIDES AND THEIR USE AS ANTICOCCIDIAL AGENTS SANKYO COMPANY LIMITED (JA) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230144-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS KCNJ4, KCNK4, KCNQ4 APLNR 1719/4885CA2 1480/4885S100A9 4010/4885
US-20240368147-A1 CYCLIN K DEGRADER CCNK, CCNI, CDK1 APLNR 4437/4885CA2 4418/4885S100A9 1857/4885
US-20060160857-A1 Thiazole-4-carboxyamide derivatives GRM1, GRM2, GRIA4 APLNR 544/4885CA2 340/4885S100A9 3058/4885
US-20060217387-A1 Acetylenyl-pyrazolo-pyrimidine derivatives NAT1, TPMT, ACAT1 APLNR 3167/4885CA2 4071/4885S100A9 3738/4885
US-20070027321-A1 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRM1 APLNR 356/4885CA2 2940/4885S100A9 4554/4885
US-20230322726-A1 QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS KCNJ4, KCNK4, KCNQ4 APLNR 1719/4885CA2 1480/4885S100A9 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.